{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:10:27Z","timestamp":1773414627844,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die Behandlung der axialen Spondyloarthritis (axSpA) umfasst neben medikament\u00f6sen Therapiema\u00dfnahmen (MTM) auch nichtmedikament\u00f6se Therapiema\u00dfnahmen (NMTM) sowie unterst\u00fctzende Ressourcen wie rehabilitationsmedizinische Therapieleistungen (RTL) und die Mitgliedschaft in Selbsthilfeorganisationen (SHO). Trotzdem bestehen deutliche Teilhabeeinschr\u00e4nkungen bei Patient*innen mit axSpA in Deutschland.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit\/Fragestellung<\/jats:title>\n                <jats:p>Untersuchung der Funktions- und Teilhabeeinschr\u00e4nkungen und Nutzung von MTM, NMTM, RTL und SHO bei Patient*innen mit axSpA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Multizentrische, deutschlandweite Beobachtungsstudie von 770 axSpA-Patient*innen (ATTENTUS-axSpA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es bestehen deutliche Funktions- und Teilhabeeinschr\u00e4nkungen bei den axSpA-Patient*innen; 39\u202f% erhielten keine Therapie mit biologischen krankheitsmodifizierenden Medikamenten (bDMARDs). Bei den NMTM wurden bewegungstherapeutische Ma\u00dfnahmen bei 54\u202f% weniger als 1\u2011mal die Woche und bei 29\u202f% 1\u2011mal pro Woche verordnet. Eine regelm\u00e4\u00dfige Bewegung f\u00fchrten 86\u202f% der Patient*innen durch, haupts\u00e4chlich in Form h\u00e4uslicher \u00dcbungen. Training im Fitnessstudio (14\u202f%) oder Vereinssport (7\u202f%) wurden seltener ausgef\u00fchrt. Eine RTL erhielten 54\u202f% der Patient*innen, und bei etwa einem Drittel lag die letzte RTL \u00fcber 5\u00a0Jahre zur\u00fcck. Es waren 13\u202f% Mitglieder in einer SHO. In dieser Gruppe fand sich eine signifikant h\u00f6here Inanspruchnahme von NMTM und RTL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Verf\u00fcgbare Behandlungsoptionen und Ressourcen werden von axSpA-Patient*innen h\u00e4ufig in geringem Ma\u00df und\/oder in niedriger Intensit\u00e4t genutzt, welches eine m\u00f6gliche Erkl\u00e4rung f\u00fcr persistierende Teilhabeeinschr\u00e4nkungen sein k\u00f6nnte. Wir beobachteten eine verst\u00e4rkte Inanspruchnahme von NMTM und RTL bei Mitgliedschaft in einer SHO.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00393-023-01410-w","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T10:03:03Z","timestamp":1695117783000},"page":"500-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nichtmedikament\u00f6se Therapiema\u00dfnahmen, Rehabilitationsleistungen und Mitgliedschaft in Selbsthilfeorganisationen bei axialer Spondyloarthritis (Die\u00a0ATTENTUS axSpA-Studie)","Nonpharmacological treatment measures, rehabilitation services and membership in patient support groups  in axial spondylarthritis  (The ATTENTUS axSpA study)"],"prefix":"10.1007","volume":"83","author":[{"given":"D.","family":"Meyer-Olson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Hammel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Haehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"1410_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Compan","year":"2021","unstructured":"Navarro-Compan\u00a0V, Sepriano\u00a0A, El-Zorkany\u00a0B et al (2021) Axial spondyloarthritis. Ann Rheum Dis 80:1511\u20131521. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221035","journal-title":"Ann Rheum Dis"},{"key":"1410_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00393-019-0670-3","volume":"78","author":"U Kiltz","year":"2019","unstructured":"Dgrh, Kiltz\u00a0U, Braun\u00a0J et al (2019) Long version on the S3 guidelines for axial spondyloarthritis including Bechterew\u2019s disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations. Z\u00a0Rheumatol 78:3\u201364. https:\/\/doi.org\/10.1007\/s00393-019-0670-3","journal-title":"Z Rheumatol"},{"key":"1410_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro\u00a0S, Nikiphorou\u00a0E, Sepriano\u00a0A et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82:19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"1410_CR4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/annrheumdis-2018-213585","volume":"77","author":"AK Rausch Osthoff","year":"2018","unstructured":"Rausch Osthoff\u00a0AK, Niedermann\u00a0K, Braun\u00a0J et\u00a0al (2018) 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77:1251\u20131260. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213585","journal-title":"Ann Rheum Dis"},{"key":"1410_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222020","author":"JM Gwinnutt","year":"2022","unstructured":"Gwinnutt\u00a0JM, Wieczorek\u00a0M, Balanescu\u00a0A et\u00a0al (2022) 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222020","journal-title":"Ann Rheum Dis"},{"key":"1410_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/annrheumdis-2021-220249","volume":"80","author":"E Nikiphorou","year":"2021","unstructured":"Nikiphorou\u00a0E, Santos\u00a0EJF, Marques\u00a0A et al (2021) 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis 80:1278\u20131285. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220249","journal-title":"Ann Rheum Dis"},{"key":"1410_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00393-021-01019-x","volume":"81","author":"U Kiltz","year":"2022","unstructured":"Kiltz\u00a0U, Buschhorn-Milberger\u00a0V, Albrecht\u00a0K et al (2022) Development of quality standards for patients with axial spondyloarthritis for use in Germany. Z\u00a0Rheumatol 81:730\u2013743. https:\/\/doi.org\/10.1007\/s00393-021-01019-x","journal-title":"Z Rheumatol"},{"key":"1410_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/annrheumdis-2019-216034","volume":"79","author":"U Kiltz","year":"2020","unstructured":"Kiltz\u00a0U, Landewe\u00a0RBM, van der Heijde\u00a0D et\u00a0al (2020) Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis 79:193\u2013201. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216034","journal-title":"Ann Rheum Dis"},{"key":"1410_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries\u00a0JF, Spitz\u00a0P, Kraines\u00a0RG et\u00a0al (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137\u2013145. https:\/\/doi.org\/10.1002\/art.1780230202","journal-title":"Arthritis Rheum"},{"key":"1410_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1055\/a-1718-2941","volume":"47","author":"SE Meyer","year":"2022","unstructured":"Meyer\u00a0SE, Hoeper\u00a0JR, Buchholz\u00a0J et\u00a0al (2022) Technische Alltagshilfen in der Rheumatologie \u2013 Was ist sinnvoll, was ist bewiesen, welche Perspektiven gibt es? Akt Rheumatol 47:33\u201342","journal-title":"Akt Rheumatol"},{"key":"1410_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/a-1041-4093","volume":"44","author":"D Meyer-Olson","year":"2019","unstructured":"Meyer-Olson\u00a0D, Hoeper\u00a0K, Sturm\u00a0C et al (2019) Rehabilitation von Patienten mit entz\u00fcndlich-rheumatischen Erkrankungen. Akt Rheumatol 44:383\u2013391. https:\/\/doi.org\/10.1055\/a-1041-4093","journal-title":"Akt Rheumatol"},{"key":"1410_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002663","author":"U Kiltz","year":"2023","unstructured":"Kiltz\u00a0U, Hoeper\u00a0K, Hammel\u00a0L et al (2023) Work participation in patients with axial spondyloarthritis: high prevalence of negative workplace experiences and long-term work impairment. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002663","journal-title":"RMD Open"},{"key":"1410_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jbspin.2015.06.012","volume":"83","author":"IH Song","year":"2016","unstructured":"Song\u00a0IH, Brenneis\u00a0C, Hammel\u00a0L et al (2016) Ankylosing spondylitis self-help organisations\u2014do members differ from non-members? Joint Bone Spine 83:295\u2013300. https:\/\/doi.org\/10.1016\/j.jbspin.2015.06.012","journal-title":"Joint Bone Spine"},{"key":"1410_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00393-013-1209-7","volume":"73","author":"K Mattukat","year":"2014","unstructured":"Mattukat\u00a0K, Thyrolf\u00a0A (2014) Social participation and activities of daily living of patients with inflammatory rheumatic diseases : support by self-help, exercise therapy and new media. Z\u00a0Rheumatol 73:42\u201348. https:\/\/doi.org\/10.1007\/s00393-013-1209-7","journal-title":"Z Rheumatol"},{"key":"1410_CR15","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett\u00a0S, Jenkinson\u00a0T, Kennedy\u00a0LG et\u00a0al (1994) A\u00a0new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J\u00a0Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"1410_CR16","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin\u00a0A, Garrett\u00a0S, Whitelock\u00a0H et\u00a0al (1994) A\u00a0new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J\u00a0Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"1410_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","volume":"77","author":"U Kiltz","year":"2018","unstructured":"Kiltz\u00a0U, van der Heijde\u00a0D, Boonen\u00a0A et\u00a0al (2018) Measurement properties of the ASAS Health Index: results of a\u00a0global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis 77:1311\u20131317. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212076","journal-title":"Ann Rheum Dis"},{"key":"1410_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/rheumatology\/kep457","volume":"49","author":"MC Reilly","year":"2010","unstructured":"Reilly\u00a0MC, Gooch\u00a0KL, Wong\u00a0RL et\u00a0al (2010) Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology 49:812\u2013819. https:\/\/doi.org\/10.1093\/rheumatology\/kep457","journal-title":"Rheumatology"},{"key":"1410_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3899\/jrheum.220239","volume":"50","author":"U Kiltz","year":"2023","unstructured":"Kiltz\u00a0U, Ahomaa\u00a0EP, van Weely\u00a0SFE et\u00a0al (2023) Clinically relevant deficits in performance tests in patients with axial spondyloarthritis. J\u00a0Rheumatol 50:351\u2013358. https:\/\/doi.org\/10.3899\/jrheum.220239","journal-title":"J Rheumatol"},{"key":"1410_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105585","author":"D Kiefer","year":"2023","unstructured":"Kiefer\u00a0D, Braun\u00a0J, Kiltz\u00a0U et\u00a0al (2023) Patients\u2019 awareness towards physical activity in the treatment of axial spondyloarthritis. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105585","journal-title":"Joint Bone Spine"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01410-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-023-01410-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01410-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:05:27Z","timestamp":1723561527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-023-01410-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1007\/s00393-023-01410-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"21 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Meyer-Olson: Mitglied des Rednerb\u00fcros f\u00fcr AbbVie, Amgen, Berlin Chemie, Bristol-Myers Squibb, Chugai, Fresenius Kabi, Galapagos, GSK, Janssen Cilag, Lilly, Medac, Merck Sharp & Dome, Novartis, Pfizer, Sandoz Hexal, Sanofi und UCB; Berater f\u00fcr AbbVie, Amgen,  Chugai, Fresenius Kabi, Janssen Cilag, Medac, Merck Sharp & Dome, Novartis, Pfizer, Sandoz Hexal, Sanofi und UCB, erh\u00e4lt Stipendien\u2011\/Forschungsunterst\u00fctzung von: Novartis. K.\u00a0Hoeper: Mitglied des Rednerb\u00fcros f\u00fcr AbbVie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal und Sanofi., Beraterin von AbbVie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal und Sanofi. L.\u00a0Hammel gibt an, dass kein Interessenkonflikt besteht. S.\u00a0Lieb und A.\u00a0Haehle: Mitarbeiter von Novartis Pharma. U.\u00a0Kiltz: Mitglied Rednerb\u00fcro f\u00fcr AbbVie, Chugai, Eli Lilly, Gr\u00fcnenthal, Janssen Cilag, MSD, Novartis, Pfizer, Roche und UCB; Beraterin f\u00fcr AbbVie, Biocad, Chugai, Eli Lilly, Fresenius Kabi, Gr\u00fcnenthal, Janssen, MSD, Novartis, Pfizer, Roche und UCB, erh\u00e4lt Stipendien\u2011\/Forschungsunterst\u00fctzung von: AbbVie, Amgen, Biogen, Fresenius, GSK, Sandoz Hexal, Novartis und Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}